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Understanding how vaccinia virus (VV) generates immunity necessitates an appreciation for how this virus interacts with dendritic cells (DC),
which are the most potent activators of naïve CD8+ T cells. In order to optimally activate naïve CD8+ T cells, DC must undergo maturation, during
which costimulatory molecules are upregulated and cytokines are produced. In this report, we show that VV infection of immature murine bone
marrow-derived DC (BMDC) failed to induce maturation. Similar results were obtained when CD8+ DC were analyzed, a subset shown
previously to be important in vivo in the generation of a vaccinia-specific response. The finding that VV infection of DC resulted in APC that were
incapable of initiating T-cell activation was surprising given the previously reported role for direct presentation in the generation of anti-VV CD8+
T-cell responses in mice. To address the potential mechanism responsible for direct presentation, we tested the hypothesis that previously matured
DC were susceptible to vaccinia virus infection and could present newly synthesized VV-derived epitopes for CD8+ T-cell activation. Our results
show, that during VV infection of mature DC, threshold levels of viral protein are produced that promote T-cell activation. These results suggest
that, even though VV cannot mature DC, previously matured DC exposed to VV can generate a VV-specific CD8+ T-cell response providing a
potential mechanism by which direct infection results in T-cell activation in vivo.
© 2006 Elsevier Inc. All rights reserved.Keywords: Dendritic cells; Viral; Antigen presentation; Cell activationIntroduction
Although it has been almost 30 years since the eradication of
smallpox (Henderson, 1976), there has been renewed interest in
poxvirus pathogenesis because of the emerging threat of its use
as an agent of bioterrorism (Henderson et al., 1999). Because of
this threat, it is not only critical that we understand the
pathogenesis of poxvirus infection, but also how immune
responses are generated following infection. Vaccinia virus
(VV) has been used extensively as a model for poxvirus
infection (Kieny et al., 1984; Paoletti, 1996; Koszinowski andAbbreviations: DC, dendritic cell; VV, vaccinia virus; BMDC, bone
marrow-derived dendritic cell; UV-VV, UV-inactivated vaccinia virus.
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doi:10.1016/j.virol.2006.09.020Thomssen, 1975; Smith and Kotwal, 2002); nonetheless, a
number of gaps remain in our understanding of the precise
mechanism by which VV generates a protective cellular
immune response. One key to understanding the generation of
anti-poxvirus immunity is the elucidation of how poxviruses
interact with dendritic cells (DC).
Dendritic cells play a key role in the initiation of a CD8+ T-
cell response as they appear to be the antigen presenting cells
that are capable of priming VV-specific CD8+ T cells in vivo
(Banchereau and Steinman, 1998; Norbury et al., 2002). In
order for DC to optimally prime naïve CD8+ T cells, DC must
undergo a process termed maturation. Upon contact with an
inflammatory stimulus such as TLR ligands, CD40 ligation, or
cytokines (e.g. IL-1, type I IFN, or TNF-α), DC migrate from
the site of antigen contact to a draining lymph node where they
are poised to activate naïve T cells (Akira et al., 2000;
Medzhitov, 2001; Caux et al., 1994; Wesa and Galy, 2001; Luft
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1994; Cumberbatch et al., 1991; Cumberbatch and Kimber,
1992). During this migration, DC upregulate the expression of
costimulatory molecules CD80 and CD86 (also known as B7.1
and B7.2) which bind CD28 on naïve T cells in an interaction
necessary for optimal T-cell activation (Harding et al., 1992;
Harding and Allison, 1993; Freeman et al., 1993). Mature DC
also secrete cytokines, such as IL-12 and type I IFN, that
provide the additional signal necessary for the acquisition of
CD8+ T-cell effector function (Curtsinger et al., 1999; Schmidt
and Mescher, 1999; Schmidt and Mescher, 2002; Curtsinger et
al., 2003; Curtsinger et al., 2005).
Previous studies of human DC have shown that VV fails to
induce maturation and therefore costimulatory molecule
expression (Engelmayer et al., 1999; Drillien et al., 2000).
These studies also showed that VV replication in immature
human DC is abortive. Importantly, inhibition of human DC
maturation occurs well before the virus kills the cell, suggesting
that, in addition to inducing death of infected DC, VV has
mechanisms that can directly inhibit maturation. Moreover,
infection of mature DC with VV only minimally altered
costimulatory molecule expression and did not induce sig-
nificant death (Engelmayer et al., 1999).
Vaccinia virus has a large arsenal of immune evasion
proteins that counteract many of the anti-viral mechanisms of
the innate and adaptive immune response. The VV proteins
encoded by the K3L and E3L genes specifically affect the cell's
response to dsRNA and therefore the expression and function of
type I IFN, a potent cytokine for DC maturation (Beattie et al.,
1991; Chang et al., 1992; Paez and Esteban, 1984; Xiang et al.,
2002). Other proteins have been found to interfere with TLR
signaling, an additional mechanism by which DC can be
matured. The protein encoded by the A46R gene blocks TLR
signaling by interacting with TLR adaptor proteins MyD88,
Toll-IL-1 receptor domain-containing adaptor-inducing IFN-
beta (TRIF), and TRIF-related adapter molecule (TRAM)
(Stack et al., 2005), while the A52R gene encodes a protein
that has been implicated in blocking TLR signaling by blocking
activation of NF-κB, a key transcription factor involved in the
induction of inflammatory gene transcription (Bowie et al.,
2000; Harte et al., 2003; Sen and Baltimore, 1986b; Sen and
Baltimore, 1986a; Baeuerle and Henkel, 1994). In addition,
proteins encoded by the N1L and K1L genes are also able to
inhibit activation of NF-κB (DiPerna et al., 2004; Bartlett et al.,
2002; Shisler and Jin, 2004). VV also produces receptor
homologs for the cytokines type I IFN (encoded by the B18R
gene) and IL-1β (encoded by the B15R gene) (Symons et al.,
1995; Colamonici et al., 1995; Smith and Chan, 1991). Each of
these proteins can potentially prevent dendritic cell maturation
and therefore have a profound effect on the generation of an
adaptive immune response.
Because VV has so many ways of potentially inhibiting DC
maturation, it may be difficult to imagine how DC infected with
VV could directly present antigen to and activate naïve CD8+ T
cells. However, direct presentation of viral antigen has been
shown to play a significant role in the priming of an anti-VV
CD8+ T-cell response in vivo (Basta et al., 2002; Shen et al.,2002). Using a VV that contains genes encoding human
cytomegalovirus proteins US2 or US11, both of which prevent
direct presentation of endogenous VV antigens, Basta et al.
showed that approximately 40% of the CD8+ T-cell response is
due to direct presentation of VVantigens. Moreover, Shen et al.
also used VVencoding US11 to show that anti-VV CD8+ T-cell
responses generated with intraperitoneal and intravenous routes
of infection were, for the most part, a result of direct
presentation (Shen et al., 2002).
In these studies, we determined the effect of VV infection on
mouse DC maturation. We found that VV did not induce mouse
DC maturation as shown by the failure of bone marrow-derived
DC (BMDC) or spleen-derived CD8+ DC to upregulate
expression of the maturation markers. Interestingly, however,
UV-inactivated VV (UV-VV) did induce upregulation of these
costimulatory molecules as well as the secretion of inflamma-
tory cytokines. As a result, UV-VV treated BMDC, but not VV-
infected BMDC, were able to activate naïve CD8+ T cells in the
presence of exogenous antigen. Infection of previously matured
DC, while abortive, resulted in the presentation of adequate
levels of newly synthesized viral protein for efficient T-cell
activation. Thus, we propose that one mechanism by which
direct presentation may occur in vivo is through virus infection
of DC that were previously matured by a signal not associated
with direct infection, e.g. cytokines or viral components
released from neighboring infected cells.
Results
VV infection of immature mouse BMDC did not induce
upregulation of costimulatory molecules
We first determined the effect of VV infection on the
upregulation of costimulatory molecules CD40, CD80, and
CD86 on murine DC. Mouse BMDC were infected with sucrose
gradient purified VV-Ova at an MOI of 0.1, 1, or 10 for 24 h.
We first looked at 24 h post-infection so that we could directly
compare our results with those obtained by others in the human
system. Expression of maturation markers on the infected cells
was compared to DC treated with LPS or UV inactivated virus
(UV-VV) for 24 h. As expected, treatment of mouse BMDC
with LPS resulted in significant upregulation of CD40, CD80,
and CD86 expression at 24 h (Fig. 1). However, infection of
mouse BMDC with VV did not induce upregulation of any of
these markers, regardless of MOI (Fig. 1). In contrast, treatment
with UV-VV resulted in a dose-dependent increase CD40,
CD80, and CD86 expression. CD40 was the least sensitive to
upregulation by UV-VV, whereas CD86 expression was
upregulated to a level that was greater than that observed with
LPS. Of note, increased expression of these markers following
treatment with UV-VV was absent at 8 h post-treatment but
maximal at 18 h and thus was delayed compared to LPS-
induced maturation (data not shown). It was possible that the
kinetics with which VV-infection induced upregulation of these
markers was delayed compared to LPS or alternatively that
there was a transient upregulation of costimulatory markers
early following infection that had returned to baseline by 24 h.
Fig. 1. VV infection fails to induce upregulation of maturation markers on murine BMDC. Mouse bone marrow cells were cultured in the presence of GM-CSF for 6
days and then treated with 300 ng/ml LPS, VV, or UV-VV for the indicated time or were mock-treated (M). The maturation phenotype of BMDC was determined by
staining with anti-CD11c in combination with antibodies to the maturation markers CD40, CD80, and CD86. (A) Histograms showing CD40, CD80, and CD86
expression levels on CD11c+ BMDC that were mock-treated, LPS-treated, infected with VV (MOI 0.1 or 10), or treated with UV-VV (MOI 10) for 24 h. (B) Average
geometric mean fluorescence intensities of CD40, CD80, and CD86 expression on BMDC treated for 24 h. (C) BMDC were infected with VV-eGFP and percent
eGFP+ was measured at 8 or 18 h to determine infectivity. (D) BMDC were stained with 7AAD to assess death. Data are representative of at least 4 independent
experiments. Cells in all analyses are following gating on the CD11c+ population.
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showed a failure of VV to induce these molecules (data not
shown). Together, these results show that UV-VV was a strong
maturation stimulus, yet live virus was not capable of inducing
maturation of mouse BMDC.
We next sought to determine the percentage of BMDC that
became infected following exposure to VV. Experiments
performed using a polyclonal anti-VV antibody followinginfection with a vaccinia virus expressing eGFP (VV-EGF-
POva) suggested that the antibody was not sensitive enough to
detect the majority of infected cells. Thus, we performed these
analyses with a VV expressing eGFP to quantitate infection.
Importantly, VV-eGFP infection did not induce BMDC
maturation, similar to the results seen with VV-Ova (data not
shown). Using an MOI of 1 or 10, approximately 80% of
BMDC were infected at 8 h as measured by eGFP expression
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was less (20%) as would be expected. By 18 h post-infection
with this low MOI, however, the percentage of infected cells
increased to approximately 75%. No eGFP expression was
detected in BMDC treated with UV-inactivated VV-eGFP. To
determine the extent of cell death, we stained cells with 7AAD
at 8 and 18 h post-infection. At 8 h pi, increased death was only
seen after infection with the high MOI (Fig. 1D). By 18 h pi,
there was a dose-dependent increase in the number of cells that
were dying. As would be expected, there was no increase in
death in cells that were treated with UV-inactivated virus.
VV infection of mouse BMDC fails to induce secretion of
inflammatory cytokines
Another property associated with DC maturation is the
ability to secrete pro-inflammatory cytokines. We used a
cytometric bead array to determine the presence of IL-6,
MCP-1, and TNF-α in the supernatants of mouse BMDC
infected with VV or treated with LPS or UV-VV. In addition,
we also determined the levels of IL-12p40 in BMDC
supernatants by ELISA and IFN-α/β using a VSV-based
bioassay. In these analyses, we found that infection with VV
did not result in significant TNF-α, IL-12p40, or IFN-α/β
secretion (Fig. 2). While BMDC infected with VV did secrete
MCP-1, the level produced was much less than that secretedFig. 2. VV infection fails to induce inflammatory cytokine secretion in murine BM
for the presence of inflammatory cytokines. (A) Levels of TNF-α, MCP-1, a
methods). (B) IL-12p40 levels in BMDC supernatants were measured by ELIS
BMDC as measured by the VSV-based IFN-α/β bioassay. Levels of IFN-α/β in p
with mock-infected BMDC (A and B) or compared with VV-infected BMDC (by LPS-treated BMDC and was inversely proportional to
MOI. A very low but detectable level of IL-6 was detected in
BMDC infected with VV (MOI-10), but this value was
minimal compared to that secreted by LPS-treated BMDC,
and IL-6 secretion was not detected following infection at an
MOI of 1 or 0.1.
In contrast, exposure of BMDC to UV-VV at an MOI of 10
induced detectable secretion of both TNF-α and IL-6, moderate
production of MCP-1 and IL-12p40, and robust production of
IFN-α/β. These results show that infection of BMDC with VV
resulted in minimal cytokine production; however, treatment
with UV-VV resulted in production of a similar profile of
cytokines as compared to LPS-treated cells, albeit at lower
levels. The exception to this was IFN-α/β, where the level
exceeded that of LPS-treated cells.
Vaccinia infection of CD8+ DC results to a failure to mature
A recent study has shown that CD8+ DC are the predominant
DC that present VV antigen in vivo following infection by the
subcutaneous or intravenous routes (Belz et al., 2004). Given
this, we investigated the effect of vaccinia infection on CD8+
DC as it was possible that the result of VV infection of this DC
subset was distinct from that observed in myeloid DC. As a
method for the in vitro differentiation of bona fide CD8+ DC is
lacking, we isolated splenic CD8+ DC for our studies. IsolatedDC. Supernatants from treated BMDC were harvested at 24 h and analyzed
nd IL-6 in BMDC supernatants as measured by CBA (see Materials and
A. (C) Type I IFN levels in BMDC supernatants relative to mock-treated
olyI:C treated BMDC supernatants were similar to LPS. *P<0.05 compared
C). Values are the average of 3 experiments.
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eGFP (VV-EGFPOva) at increasing MOI, and viability and
maturation were assessed at 12 h. This virus also allowed direct
determination of infected cells. As expected, there was a dose-
dependent increase in the percent of eGFP+ CD8α+ DC 12 h pi
(Fig. 3A). VV infection did not result in death at levels
significant above mock infection CD8α+ DC. However, others
have noted high levels of nonspecific death in uninfected
splenic CD8α+ DC after overnight culture (Rizzitelli et al.,
2005) and thus the death of infected cells is hard to assess above
this background (Fig. 3B). As has been shown previously
(Rizzitelli et al., 2005), isolated CD8+ DC cultured overnight
upregulated CD86 compared to cells tested directly ex vivo
(data not shown). Addition of LPS resulted in further
upregulation of this maturation marker (Fig. 3). When CD86
expression was analyzed on the infected cells, a significantly
reduced maturation was observed, consistent not only with a
failure of vaccinia virus infection to induce maturation, but also
a block in the spontaneous maturation that results from
overnight culture. At 18 h pi, CD8α+ DC treated with LPSFig. 3. Infection of CD8+ DC with vaccinia virus fails to induce maturation.
CD8+ DC enriched from the spleen of C57BL/6 mice were infected with VV-
EGFPOva (MOI=0.1, 1, or 10) for 12 h. Cells were then stained with antibodies
to CD11c, CD8, and CD86 or with 7AAD. Data are obtained following gating
on the CD11c+ CD8+ cells in the live cell gate at 12 h post-infection. (A) Percent
eGFP+, (B) percent 7AAD+, and (C) MFI of CD86 expression are shown. Data
are the average of 3 experiments.have even further upregulated CD86 expression, while VV-
EGFPOva-infected cells still exhibit an immature phenotype
(data not shown). Of note, a small fraction of cells do undergo
limited maturation. These cells, however, are a very small
percentage of the starting DC population. Together, these data
suggest that, similar to the in vitro generated myeloid DC, VV
fails to mature the vast majority of CD8+ DC.
VV-infected BMDC fail to activate naïve CD8+ T-cell
proliferation and function
As it is well established that the increased expression of
costimulatory molecules and the secretion of inflammatory
cytokines are essential for DC to effectively prime a CD8+ T-
cell response (Harding et al., 1992; Harding and Allison, 1993;
Freeman et al., 1993; Curtsinger et al., 1999; Curtsinger et al.,
2003; Schmidt andMescher, 1999; Schmidt and Mescher, 2002;
Curtsinger et al., 2005), we tested the ability of VV-infected DC
to activate naïve CD8+ T cells. Given the similarity in the
maturation of CD8+ DC and the BMDC following infection
with VV, we used BMDC for these assays because of the
difficulty in obtaining adequate numbers of CD8+ DC for our
studies. Treated BMDC were co-cultured with LCMV gp33–41
specific CD8+ T cells from P14 TCR transgenic mice. Use of
this system allowed us to determine the functional significance
of changes in the maturation state of the DC that resulted from
VV exposure while keeping constant the amount of exogenous
peptide (LCMV gp33–41). Fig. 4A shows a representative
experiment from our analyses of CFSE-labeled LCMV gp33–41-
specific CD8+ T cells that were cultured for 3 days with BMDC
previously treated with LPS, VV, or UV-VV. Fig. 4B and C
shows the averages from 3 independent experiments. At
limiting concentrations of gp33–41 peptide (10
−10M), LPS-
treated BMDC induced significant proliferation and function of
naïve gp33–41-specific CD8
+ Tcells. On average, approximately
70% of cells entered division following stimulation with BMDC
matured by exposure to LPS, and of the dividing cells at least
65% produced IFN-γ.
In contrast, BMDC infected with VV induced very minimal
proliferation of naïve gp33–41-specific CD8
+ T cells; the
percentage of cells that had divided following co-culture with
BMDC infected with an MOI of 0.1 or 1 was similar to that
observed following culture with mock-infected cells. For cells
infected with the highest MOI (10), the percent divided was
below that of mock-infected BMDC when the 10−9 M peptide
concentration was used. Furthermore, CD8+ T cells cultured
with VV-infected BMDC pulsed with limiting peptide con-
centrations were not functional as shown by their failure to
produce IFN-γ following peptide stimulation. Mock-treated
BMDC or those infected with VV were all similar in their ability
to promote the acquisition of effector function in naïve T cells.
Of note, at high concentrations of peptide (10−8 M), T cells co-
cultured with VV-infected BMDC underwent proliferation and
gained function to a level similar to that observed following
culture with LPS-treated BMDC, demonstrating that the failure
of T cells to proliferate when co-cultured with VV-infected
BMDC was not the result of the presence of virus that infected
Fig. 4. VV-infected murine BMDC do not activate naïve CD8+ T cells in the presence of limiting concentrations of exogenous peptide antigen. Mouse BMDC were
treated with LPS or UV VVor infected with VV for 24 h. DC were then pulsed with titrated concentrations of LCMV gp33–41 peptide. Pulsed BMDCwere washed and
co-cultured with CFSE-labeled splenocytes from naive Rag−/− gp33–41-specific P14 TCR transgenic mice for 3 days. (A) Proliferation and function of P14 CD8
+ Tcells
after co-culture with unpulsed or 10−super 10 M pulsed BMDC treated under the designated conditions. (B) Percent of P14 CD8+ T cells that divided after co-culture
with BMDC pulsed with varying concentrations of gp33–41 peptide. (C) Percent maximal IFN-γ production by divided P14 CD8
+ T cells after co-culture with BMDC
pulsed with titrated concentrations of gp33–41 peptide. BMDC infected with VV (MOI=0.1, 1, or 10) or UV VV (MOI=10) are shown. Values in B and C are the
average of 3 experiments.
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activation.
Similar to LPS-treated cells, BMDC exposed to UV-VV
induced T-cell proliferation and function. Proliferation was
similar in both the percentage of cells that entered division and
the proliferation index, which is a measure of the average
number of divisions undergone by the T cells that entered
division (2.6±SE 0.46 for LPS and 2.7±SE 0.27 for UV-VV).
Additionally, a similar percentage of CD8+ T cells cultured with
BMDC treated with UV-VV produced IFN-γ compared with
cultures stimulated with LPS-matured BMDC (70% vs. 68%)
(Fig. 4C). This is consistent with our results from Figs. 1 and 2
showing that BMDC treated with UV-VV at an MOI of 10
exhibited high expression of the costimulatory molecules CD80
and CD86 and secreted inflammatory cytokines. Together, these
data show that VV infection rendered BMDC incapable of
stimulating naïve CD8+ T-cell proliferation and function at
limiting concentrations of peptide antigen that were capable ofpromoting high levels of proliferation and function when LPS-
matured or UV-VV-matured DC were used as APC.
VV-infected BMDC exhibit decreased antigen presentation
While our data from Figs. 1 and 2 would suggest that the
failure of VV-infected DC to activate naïve T cells was because
of the lack of costimulatory molecule expression, it was
possible that VV infection resulted in decreased antigen
presentation following peptide loading that also contributed to
this effect. To address this issue, BMDC infected with VV or
matured with LPS were pulsed with varying concentrations of
LCMV gp33–41 peptide. BMDC were then co-cultured with an
established gp33–41-specific CTL line and IFN-γ production
assessed as a readout for peptide presentation. LPS-treated
BMDC induced half-maximal IFN-γ production at approxi-
mately a half-log lower concentration of antigen compared to
mock-infected BMDC. This is consistent with previous studies
Fig. 5. Decreased antigen presentation by VV-infected BMDC. Mouse BMDC
were mock-treated, treated with LPS, or infected with VV (MOI=0.1, 1, or
10) for 18 h and then pulsed with varying concentrations of gp33–41.
Following washing to remove unbound peptide, BMDC were co-cultured with
a gp33–41-specific CTL line for 5 h in the presence of GolgiPlug. IFN-γ
production was determined by FACS analysis and expressed as percent
maximal IFN-γ production. Data are the average of 3 independent
experiments.
Fig. 6. dMurine BMDC previously matured with LPS and infected with
VV-gp33–41 are capable of activating naive P14 gp33–41-specific CD8
+ T cells.
Mouse BMDC were treated with LPS (L) for 18 h followed by pulsing with
10−10 M gp33–41, infection with VV-gp33–41, or exposure to UV VV-gp33–41 for
12 h. Virus treatments were performed with MOIs of 0.1, 1, and 10. Treated
BMDC were co-cultured for 3 days with CFSE-labeled splenocytes from naive
gp33–41-specific P14 TCR transgenic mice. (A) Percent of gp33–41-specific
CD8+ T cells that entered division. (B) Percent of P14 T cells that produced IFN-
γ+ following restimulation at the end of the three-day co-culture period. Values
are the average of 3 experiments.
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(Kukutsch et al., 2000; Li et al., 2001; MacAry et al., 2001).
Infection with VV resulted in a dose-dependent increase in the
amount of peptide required to induce half-maximal IFN-γ
production in the CTL lines, in that the higher the MOI, the
greater the amount of peptide required (Fig. 5). This suggested
that VV infection resulted in a partial block in antigen
presentation in the context of MHC class I on the surface of
BMDC.
While VV infection resulted in a decrease in antigen
presentation in BMDC, this does not fully explain the inability
of VV-infected BMDC to activate naïve CD8+ T cells in the
presence of limiting concentrations of exogenous antigen. The
pattern of induction of proliferation in naïve gp33–41-specific
CD8+ T cells followed the pattern of antigen presentation as
readout by the CTL line, suggesting that the level of presented
peptide is playing a large role in controlling the entry of cells
into division. However, this is not the case with elicitation of
effector function since mock- and VV-infected BMDC were
equally incapable of eliciting IFN-γ production from naïve
CD8+ T cells, despite the fact that mock-infected BMDC were
technically presenting more peptide (Fig. 4C). This result
suggested that the lack of costimulatory molecule expression
was playing a more dominant role in the acquisition of effector
function in this assay, although peptide levels may still be
contributing to the effect. These data make the important point
that vaccinia virus utilizes a number of mechanisms to
undermine generation of the immune response.
Mature BMDC infected with VVare capable of activating naïve
CD8+ T cells
It has been shown that a significant amount (∼40%) of the
CD8+ T-cell response to VV in vivo is due to direct priming ofnaïve CD8+ T cells by infected DC (Basta et al., 2002). Our
findings raised the question of how this could occur if infected
DC undergo maturation as has been shown to be necessary for
efficient naïve CD8+ T-cell activation. We hypothesized that
DC matured via an alternative signal could become infected
with VV leading to presentation of viral antigen. To test this
possibility, BMDC were treated with LPS for 20 h, a period of
time which should allow for maximal maturation. Matured DC
were then infected with VV for 12 h, and the expression of
CD40, CD80, and CD86 was determined. We found that
BMDC pre-treated with LPS retained high expression of these
markers following infection with VV at an MOI of 0.1, 1, and
10 (data not shown). We also found that VV did not induce
significant death (as shown by staining for active caspase 3) of
BMDC pre-treated with LPS (data not shown). These results
showed that VV did not exhibit cytopathic effects and had
minimal impact on maturation marker expression on murine
DC that were mature at the time of infection. When mature
BMDC were infected with VV-eGFP at MOIs of 10, 1, or 0.1–
10%, 12% and 5% of cells were eGFP+ at 20 h pi, in stark
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80% were eGFP+ at these time points (data not shown). These
data suggest that mature BMDC are relatively non-permissive
to infection.
We next determined whether the previously matured mouse
BMDC infected with VV were capable of activating naïve
CD8+ T cells. To test this possibility, BMDC previously
matured by LPS treatment were infected with VV-gp33–41 and
cultured with naïve P14 gp33–41-specific CD8
+ T cells for 3
days (similar to what was done in Fig. 4) (Fig. 6). Proliferation
and function of these CD8+ T-cell populations were compared
to naïve P14 T cells cultured with mock or LPS-treated BMDC
pulsed with 10−10 M gp33–41. BMDC matured with LPS and
subsequently infected with VV-gp33–41 (MOI=1 or 10) were
capable of inducing proliferation and function of P14 T cells
similar to LPS-matured BMDC pulsed with 10−10 M gp33–41
(Fig. 6). Similar percentages of cells entered division and the
average number of divisions the T-cell population underwent
(division index) were similar (1.3±0.1 (MOI=1), 1.2±0.1
(MOI=10), and 1.7±0.1 (LPS)). As expected, LPS-matured
BMDC treated with UV-VV did not induce proliferation or
function of P14 CD8+ T cells, demonstrating the requirement
for VV protein expression following infection in order for
presentation of gp33–41 to occur. Furthermore, no activation was
apparent when LPS-matured BMDC infected with VV-VPE16,
a recombinant VV expressing the HIV gp160 protein was used
(data not shown). Together, these data suggest that VV protein,
albeit at low levels, is being produced in previously matured
BMDC exposed to VV. Moreover, mature DC exposed to VV
are capable of activating naïve CD8+ T cells to proliferate and
acquire effector function.
Discussion
Previous studies in mice suggested that DC are the relevant
APC for priming a VV-specific CD8+ T-cell response in vivo
(Banchereau and Steinman, 1998; Norbury et al., 2002). In this
report, we investigated the capacity of VV-infected murine DC
to undergo maturation as a result of infection and subsequently
to activate naïve CD8+ T cells. We demonstrated that VV-
infected mouse BMDC did not undergo maturation as measured
by the upregulation of costimulatory markers and the produc-
tion of cytokines and were thus not capable of activating naïve
CD8+ T cells in the presence of limiting concentrations of
exogenous antigen. The majority of our analyses were
performed using immature BMDC, which are predominantly
of myeloid phenotype, as large numbers of these cells can be
readily generated. However, as a recent study suggested that
CD8α+ DC are the predominant activators of vaccinia-specific
CD8+ T cells in vivo following infection by the intravenous or
subcutaneous routes (Belz et al., 2004), we also tested the
ability of vaccinia infection to induce maturation of CD8α+ DC
isolated from the spleen. As with the in vitro generated myeloid
DC, CD8α+ DC infected with vaccinia virus failed to undergo
maturation. In our analysis of the infected cells that survived
after overnight culture, we did observe a small percentage of
cells that underwent limited maturation. Given the smallpercentage of the initial population that these would have
constituted, one possibility is that these cells were farther along
in their maturation at the time of infection, thereby limiting the
cytopathic effect of the virus as was observed for myeloid DC.
However, determining whether this is the case will require
further investigation. Nonetheless, in general, the effect of VV
infection on the maturation of myeloid and CD8+ DC appeared
similar.
Previous studies in mice have shown that direct presentation
by infected APC contributes significantly to the generation of
the VV-specific CD8+ T-cell response (Basta et al., 2002; Shen
et al., 2002). This finding was seemingly contradictory to our
studies showing that infection with VV failed to trigger DC
maturation to become proficient activators of naïve T cells. Of
note, the failure to undergo maturation was observed at times
post-infection between 6 and 48 h (data not shown and Fig. 1),
encompassing the timeframe during which Norbury et al.
reported presentation of vaccinia virus proteins in the draining
lymph node (Norbury et al., 2002).
Given the failure of VV-infected immature DC to activate
CD8+ T cells, we tested the possibility that previously
matured DC were susceptible to infection with VV and
could thereby act directly as APC capable of activating naïve
CD8+ T cells. In support of this hypothesis, we found that
BMDC matured by LPS and subsequently infected with VV-
gp33–41 retained expression of maturation markers and were
able to activate naïve gp33–41-specific CD8
+ T cells. This
ability of previously matured DC to present vaccinia peptides
is in agreement with a recent report form Wilson et al., which
showed that previously matured dendritic cells could present
viral antigen following HSV infection (Wilson et al., 2006).
Hence, the ability of infected, mature DC to directly present
viral antigen at a level adequate for naïve T-cell activation
may provide a potential mechanism to reconcile the seemingly
contradictory findings that direct presentation can occur in
vivo and that infection of immature DC is cytopathic and fails
to induce maturation. While it remains a formal possibility
that cross-presentation could contribute to the T-cell activation
observed in our infected mature BMDC cultures, we believe
that this is highly unlikely given the following: (1) previously
matured BMDC make very little viral protein, limiting the
amount of antigen available for cross-presentation, (2) the
infection is not cytopathic also limiting the antigen source and
(3) mature BMDC are not efficient at cross-presentation
(Hotta et al., 2006).
While the possibility of previously matured DC becoming
infected with VV and directly priming naïve CD8+ T cells is
attractive, we realize that additional scenarios are possible
following infection with VV in vivo that could also contribute to
direct priming of CD8+ T cells. One possibility is that VV can
mature DC of a different type, such as plasmacytoid DC.
However, although these DC have been shown to produce
copious amounts of IFN-α/β that may promote maturation of
neighboring DC, their ability to prime naïve T cells in vivo
remains controversial (Facchetti et al., 1988; Siegal et al., 1999;
Nakano et al., 2001; Asselin-Paturel et al., 2001; Krug et al.,
2003; Schlecht et al., 2004).
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treatment of BMDC with UV-inactivated virus resulted in
upregulation of CD40, CD80, and CD86 as well as the
production of a number of cytokines. Upregulation of CD86 by
UV-inactivated virus is in agreement with results observed for
human in vitro generated DC (Drillien et al., 2004). This result
opens the door to the possibility that vaccinia virus contains a
TLR agonist, as has been reported for a number of other viruses
such as measles virus (TLR2), respiratory syncytial virus, and
mouse mammary tumor virus (both TLR4) (Bieback et al.,
2002; Kurt-Jones et al., 2000; Rassa et al., 2002). Alternatively,
a non-TLR mediated event may be responsible for the
maturation signal. Further studies are required to discriminate
among these possibilities.
As previously described, VV encodes for a number of
immune evasion proteins, namely cytokine receptor homo-
logues and inhibitors of TLR signaling (Beattie et al., 1991;
Chang et al., 1992; Paez and Esteban, 1984; Xiang et al., 2002)
(Stack et al., 2005) (Bowie et al., 2000; Harte et al., 2003; Sen
and Baltimore, 1986b; Sen and Baltimore, 1986a; Baeuerle and
Henkel, 1994; DiPerna et al., 2004; Bartlett et al., 2002; Shisler
and Jin, 2004; Symons et al., 1995; Colamonici et al., 1995;
Smith and Chan, 1991). In VV-infected BMDC supernatants,
we could not detect significant levels of TNF-α, IFN-γ, and
functional IFN-α/β. Certain strains of VV do produce a
cytokine receptor homologue for TNF-α; however, the WR
strain used in our studies is not among them (Upton et al.,
1991; Howard et al., 1991). Furthermore, while the WR strain
does produce an IFN-γ cytokine receptor homologue, studies
have shown that it has a very low binding affinity for mouse
IFN-γ (Alcami and Smith, 1995; Mossman et al., 1995).
Hence, we do not believe that the inability to detect these two
cytokines is due to a masking effect of any VV-derived
cytokine binding protein. The WR strain of VV does produce a
cytokine receptor homologue for type I IFN, which may
contribute to the inability of VV to induce DC maturation and
the inability of supernatants from infected BMDC to protect
from VSV-mediated cytolysis in our bioassay (Symons et al.,
1995; Colamonici et al., 1995).
Previous studies with the human system have shown that
cytopathic effects in VV-infected DC are delayed out to 48 h
post-infection. It was then reasoned that the inability of VV to
mature human DC was due to immune evasion proteins. In our
studies with VV-eGFP, we observed that, by 18 h post-
infection with an MOI of 10, most BMDC were infected and
undergoing apoptosis as shown by caspase 3 activation and
7AAD staining (Fig. 1 and data not shown). However, at 8 h
post-infection, before the observation of widespread cyto-
pathic effects, we see no increase in the expression of
maturation markers in infected or uninfected cells (data not
shown). These results leave open the possibility that VV
immune evasion proteins can play a role in the failure to
induce DC maturation at early times before the initiation of
cell death. Alternatively, the ability of vaccinia virus infection
to induce maturation may simply be kinetically delayed
compared to maturation signals like LPS (as would be
suggested by the increase in maturation markers seen at 8 hpost-treatment of BMDC with LPS, but not UV-VV). In
support of this, infection of BMDC followed by LPS treatment
8 h later appeared to “rescue” the BMDC, resulting in
maturation marker expression similar to in pattern, but lower
in magnitude compared to LPS alone. Not surprisingly, LPS
treatment following 24-hour infection did not induce any
maturation (data not shown).
Because the mouse is used as a model for the human anti-
VV immune response, it is important that its use be validated
to the greatest extent possible. One area of importance is the
regulation of DC maturation following infection. In our
studies, we found many parallels in the results of VV
infection of murine and human DC. Furthermore, these
studies provide novel insights into the outcome of infection of
CD8+ DC, a subset not previously analyzed. Infection of both
human and murine DC results in cytopathic effects. Also in
both cases there is a failure to induce upregulation of
costimulatory molecules. Together, these findings provide
support for the use of this model in understanding the
generation of protective responses following infection with
vaccinia virus.
In summary, our data show that vaccinia virus is incapable of
triggering maturation of in vitro differentiated murine BMDC or
splenic CD8+ DC following infection and as a result infected
DC are inefficient activators of naïve CD8+ T cells. However,
VV can initiate infection of mature DC that, even though
abortive, allows for the production of a low level of viral protein
that is adequate for the activation of naïve CD8+ T cells. In
contrast to infectious virus, exposure to UV inactivated virus
induced robust DC maturation suggesting that viral components
contain a DC maturation signal. Thus, one possibility is that
viral products released from infected cells or other inflamma-
tory signals produced during vaccinia infection promote DC
maturation. Matured DC subsequently abortively infected with
VV could then potentially activate virus-specific CD8+ T cells
in vivo. These results provide new insights into the regulation of
both DC maturation and CD8+ T-cell activation as a result of
poxvirus infection.
Materials and methods
Mice and cell lines
C57BL/6 mice were purchased from the Frederick Cancer
Research and Development Center (Frederick, MD). Rag−/− P-
14 lymphocytic choriomeningitis virus (LCMV) gp33–41-
specific T-cell receptor (TCR) transgenic mice on a C57BL/6
background were purchased from Taconic. NTCC L929 is a
fibroblast cell line derived from C3H/An (H-2k) mice grown in
Dulbecco's modified Eagle's medium (Invitrogen, Grand
Island, NY) supplemented with 10% fetal calf serum (HyClone,
Logan, UT), L-glutamine, sodium pyruvate, nonessential amino
acids, HEPES, penicillin, streptomycin (BioWhittaker, Walk-
ersville, MD), and 5×10−5 M 2-mercaptoethanol. All research
performed on mice in this study complied with federal and
institutional guidelines set forth by the Wake Forest University
Animal Care and Use Committee.
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The protocol used to generate BMDC was similar to that
used by Inaba et al. (1992). Bone marrow was harvested from
the femurs and tibias of mice, and RBC were lysed with
ammonium chloride buffer (BioWhittaker, Walkersville, MD).
Bone marrow cells were then plated at 5×105 cells/well in a 24-
well plate in RPMI 1640 medium (Invitrogen, Grand Island,
NY) supplemented with 10% fetal calf serum (HyClone, Logan,
UT), HEPES, gentamicin sulfate (BioWhittaker, Walkersville,
MD), 5×10−5 M 2-mercaptoethanol, 50 ng/ml recombinant
granulocyte-macrophage colony-stimulating factor (GM-CSF)
(Biosource, Camarillo, CA). Every 2 days, the cell culture
medium of the BMDC cultures was removed followed by the
addition of fresh medium containing 50 ng/ml recombinant
GM-CSF.
Isolation of CD8+ DC from the spleen
Minced spleens from C57BL/6 mice were incubated in the
presence 100 μg/ml Collagenase D (Roche, Indianapolis, IN)
for 30 min at 37 °C. The tissue was then passed through a 70 μm
filter. CD11c+ cells were enriched by negative selection using
the using Miltenyi microbeads as per the manufacturer's
instructions (Miltenyi Biotec, Auburn, CA). In some cases,
CD8+ DC were subsequently isolated by positive selection.
Viruses
The recombinant vaccinia viruses expressing ovalbumin,
VV-Ova, and VV-EGFPOva were a kind gift from J. Bennink
(NIH). VV-vPE-16 used as a control virus is a recombinant
vaccinia virus construct that expresses the gp160 protein from
the IIIB strain of human immunodeficiency virus and was a
kind gift of Patricia Earl and Bernard Moss (National Institute
of Allergy and Infectious Diseases, Bethesda, MD) (Earl et al.,
1991). VV-gp33–41, a recombinant VV expressing the lympho-
cytic choriomeningitis virus gp33–41 epitope, was a kind gift
from J.M. Grayson and was prepared as described previously
(Whitton et al., 1993). VV were sucrose gradient purified prior
to infection of dendritic cells. Wild-type vesicular stomatitis
virus (VSV) was a gift from Douglas Lyles (Wake Forest
University School of Medicine) and was grown as previously
described (Lyles et al., 1996).
DC infection and treatments
Virus infections and treatments were performed directly in
the wells where the BMDC were generated to avoid maturation
of cells as a result of manipulation. VV-Ova was diluted in
RPMI and added to the BMDC cultures at a multiplicity of
infection (MOI) of 0.1, 1, or 10 PFU/cell. BMDC treated with
300 ng/ml lipopolysaccharide (LPS) (Sigma, St. Louis, MO)
were used as a positive control for fully matured cells. UV
inactivation of virus was carried out using the standard 254 nm,
115-V, 1A lamp (Ultra Lum, CA) for 20 min at a distance of
6.5 cm. These conditions destroyed all detectable infectiousunits. For infection of CD8+ DC, cells were cultured overnight
(12 h) in the presence of 100 ng/ml rGM-CSF to increase
viability (Rizzitelli et al., 2005).
Cell staining and flow cytometry
At various times following treatment, VV-Ova-infected,
mock-infected, and LPS (300 ng/ml)-treated DC were stained
with the following antibodies: allophycocyanine-conjugated
anti-CD11c together with phycoerythrin-conjugated anti-CD40,
anti-CD80, or anti-CD86 antibodies (PharMingen, San Diego,
CA). The cells were blocked with Fc block prior to staining to
prevent nonspecific binding of antibodies. Flow cytometry was
performed using a FACSCalibur and the data analyzed with
CellQuest Pro software (both from BD, San Diego, CA).
Cytokine detection
Supernatants from BMDC cultures that were VV-Ova-
infected, mock-infected, or LPS-treated were analyzed at
various times following treatment for the presence of cytokines.
Interleukin-(IL-)12p40 was detected by capture enzyme-linked
immunosorbent assay (ELISA). IL-12p70, tumor necrosis
factor alpha (TNF-α), IL-10, IL-6, IFN-γ, and MCP-1 were
detected using the cytometric bead array (CBA) kit as per the
manufacturer's instructions (BD, San Diego, CA).
IFN-α/β was measured using the VSV-based IFN-α/β
bioassay. This assay measures the amount of IFN-α/β present
based on the decreased susceptibility of L929 cells to VSV-
mediated cytolysis. Briefly, infectious virus in the supernatants
from BMDC cultures was inactivated at 4 °C overnight by acid
treatment at pH 2, the acid was neutralized, and serial dilutions
were incubated with L929 cells in 96-well plates overnight at
37 °C. As a standard, cells were incubated with serial fivefold
dilutions of IFN (Universal IFN-α/β; PBL Biomedical
Laboratories, New Brunswick, NJ). The samples were aspi-
rated, and cells were challenged with wild-type VSVat an MOI
of 8 in 100 μl of medium. Controls included cells infected with
wild-type VSV alone and cells that were not challenged with
wild-type VSV. Cells were incubated overnight at 37 °C,
medium was aspirated, and cells were fixed with 95% ethanol.
Cells were then stained with a 0.1% crystal violet solution in
methanol. Absorbance was read at 540 nm on an ELISA reader
(Ahmed et al., 2003).
Assessment of naïve T-cell proliferation and function
On day 6 post-culture, BMDC were mock-treated, LPS-
treated, UV-VV-Ova-treated, or infected with VV-Ova. At the
indicated times following treatment, the cells were pulsed with
(LCMV) gp33–41 peptide. These cells were then washed to
remove soluble peptide. Spleens were harvested from P14
mice (Rag−/−) and processed to yield single cell suspensions.
Splenocyte populations were at least 88% CD8+ T cells. CFSE
(5 μM) (5- and 6-carboxyfluorescein diacetate, succinimidyl
ester, Molecular Probes, Eugene, OR)-labeled, antigen-specific
P14 LCMV gp33–41-specific TCR transgenic splenocytes were
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days at a ratio of 10:1 at 37 °C in 96-well plates.
Alternatively, CFSE-labeled P-14 gp33–41-specific TCR trans-
genic splenocytes were co-cultured with DC matured with
LPS and either infected with VV-gp33–41 or pulsed with
gp33–41 peptide for 3 days at a ratio of 10:1. On day 3 of
culture, cells were harvested and stimulated with 10−6 M
peptide for 5 h in the presence of GolgiPlug (BD PharMingen,
San Diego, CA). Cells were then stained with anti-CD8
antibody, fixed and permeabilized, and IFN production
assessed by intracellular staining. Proliferation was determined
by the decrease in CFSE intensity as measured by flow
cytometry. Analysis and quantitation of data were performed
using FlowJo software (FlowJo, Ashland, OR).
Assessment of antigen presentation
On day 6 post-culture, BMDC were mock-treated, LPS-
treated, or infected with VV-Ova. Twenty-two hours following
treatment, the cells were pulsed with (LCMV) gp33–41 peptide.
These cells were then washed to remove soluble peptide and co-
cultured at a CTL to DC ratio of 2:1 for 5 h with a gp33–41-
specific CTL line in the presence of GolgiPlug (BD PharMin-
gen, San Diego, CA). Cells were then stained with anti-CD8
antibody, fixed and permeabilized, and IFN production assessed
by intracellular staining.
Statistical analysis
A paired Student's t test was used to compare significance of
individual time points and BMDC treatments. P≤0.05 was
considered statistically significant.
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